Tryp Therapeutics Inc.
TRYPF · OTC
2/29/2024 | 11/30/2023 | 8/31/2023 | 5/31/2023 | |
|---|---|---|---|---|
| Market Cap | $1,637 | $4,851 | $6,512 | $7,720 |
| - Cash | $1 | $2,064 | $345 | $1,256 |
| + Debt | $16 | $5,013 | $2,103 | $1,229 |
| Enterprise Value | $1,651 | $7,800 | $8,270 | $7,694 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$1 | -$918 | -$1,050 | -$598 |
| % Margin | – | – | – | – |
| Net Income | -$3 | -$1,161 | -$1,690 | -$656 |
| % Margin | – | – | – | – |
| EPS Diluted | -0 | -0.012 | -0.018 | -0.007 |
| % Growth | 99.7% | 31.4% | -157.4% | – |
| Operating Cash Flow | -$7 | -$969 | -$1,119 | -$743 |
| Capital Expenditures | $0 | $0 | $0 | -$8 |
| Free Cash Flow | -$7 | -$969 | -$1,119 | -$751 |